Private Advisory · Healthcare Vertical SaaS & RCM Services
Most healthcare SaaS and services founders hit $1M and keep selling. They hit $2M and keep selling. By $3M they know something is wrong — but they can't stop long enough to fix it.
Private advisory for founders of healthcare vertical SaaS, AI, and RCM services companies navigating the valley of death between $1M and $5M.
Request a ConversationShort, direct notes on what actually holds up when you're navigating growth and high-stakes revenue decisions in healthcare and vertical B2B markets.
At $1M you were scrappy and it worked. At $3M you're stretched thin and it's starting to show. The deals that close are the ones you're in. The ones you're not in — drag or stall. You know it won't scale. You just haven't found the time to fix it.
"You can't read the label when you're inside the bottle."
When you're the founder, the seller, and the operator — you can't see what's actually driving results. Or where the risk is building. The signals are there. You just can't read them from inside.
That's not a weakness. It's physics.
Inside the markets your buyers operate in — where deals stall, risk shows up late, and bad decisions cost real money. That includes building, scaling, and exiting a national healthcare revenue cycle management services company. I know where deals go to die in healthcare procurement because I've lost them there. And I know what it looks like when a founder-led sales motion stops scaling — because I've lived through it.
Selling workflow displacement before the category had a name. Buyers who didn't know they needed it. I learned early what it costs to be wrong about a deal you thought was close.
Complex enterprise sales as the internet redefined every assumption about how organizations bought technology. Long cycles. Committee decisions. Internal politics that killed deals that should have closed.
I didn't advise a healthcare company. I built one.
Co-founded, scaled, and exited a national healthcare revenue cycle management services company. For over a decade, I operated inside the exact market your buyers live in. Payroll on the line. Client relationships on the line. Personal capital on the line. Every quarter.
I know what it feels like when a deal you need doesn't close. When a key client relationship starts to wobble. When the team you built isn't carrying the number and you're not sure if it's them or you.
That's not something you learn from the outside. That's something that costs you.
Each of those cycles looked different on the surface. The underlying dynamics — founder dependency, buyer resistance, category disruption, team scaling — were identical. What I bring isn't a framework. It's decades of learning what works when real money is on the line.
Between $1M and $5M, most healthcare SaaS and services companies hit the same wall. The founder is the sales motion. The team is orbiting it. Nothing moves unless you're involved — and you already know that's not sustainable.
So you hire. It doesn't hold. You build a process. It doesn't stick. You hand off a deal. It stalls. And every quarter you tell yourself next quarter you'll fix it — but next quarter you're still in every deal.
The trap tightens because no one has actually looked at what's real versus what just looks like progress. Not the pipeline number. Not the activity. What's actually real.
That's where I come in.
I don't come in with a playbook. I come in with decades of hard-learned experience and a structured working session designed to tell you what's actually happening inside your revenue engine before you make your next expensive decision.
The founders who get through the valley of death don't do it by working harder. They do it by making one or two better decisions at the right moment — usually with someone in the room who has been through it before.
Most companies don't need more advice. They need an accurate diagnosis.
The Mercury Test is a structured 90-minute working session — not a pitch, not a presentation — designed to identify what's actually driving results inside your revenue engine before any decisions about what to change.
We look at where deals are real, where they're not, and why.
You leave with a written report. Some founders use it internally. Others decide to engage more deeply. Both outcomes are fine.
Learn About the Mercury Test →It's not broadly distributed. It's an operating-level resource — the kind of material that only makes sense once we've had a real conversation about what's actually happening in your business.
It's earned its way into most serious conversations I've had. The founders who've seen it don't ask for a framework after that.
"If this sounds like something worth earning — that's the right instinct."Request a Conversation
Field Memos are not marketing posts. They're the kind of direct thinking founders share with their teams when something finally explains what they've been seeing.
No generic advice. No frameworks borrowed from someone else's war. Written specifically for founders navigating complex healthcare and vertical B2B markets under pressure.
Read Field Memos →Field Memos go out when there's something worth saying — not on a publishing calendar. If you're building a healthcare SaaS or services company between $1M and $5M, these will feel uncomfortably familiar.
No frequency commitments. No sales sequences. Unsubscribe anytime.
Most B2B sales problems aren't execution problems. They're judgment problems. Judgment about when to push and when to wait. When discovery is real and when it's theater. When a deal is alive and when it's already dead and nobody's said it yet.
This isn't a sales playbook. It's what decades of field experience — the kind that cost something — actually produces. For the founder who's done with frameworks and needs to think more clearly under pressure.
Get It on Amazon →Most work begins through private introductions. Some founders reach out directly. Either way, the first conversation is just that — a conversation. Not a pitch. Not a qualification call. A direct look at what's actually happening.
Request a Conversation